Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 10903150
Chiariello M, Gomez E, Gutkind JS (2000) Regulation of cyclin-dependent kinase (Cdk) 2 Thr-160 phosphorylation and activity by mitogen-activated protein kinase in late G1 phase. Biochem J 349 Pt 3, 869-76 10903150
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y15-p - CDK2 (mouse)
Modsite: EKIGEGtyGVVyKAK SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): Y15‑p, CDK2 iso2 (human): Y15‑p, CDK2 (mouse): Y15‑p, CDK2 (rat): Y15‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
PD98059 PDGF no effect upon treatment-induced increase

T160-p - CDK2 (mouse)
Modsite: GVPVRtYtHEVVTLW SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): T160‑p, CDK2 iso2 (human): T160‑p, CDK2 (mouse): T160‑p, CDK2 (rat): T160‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
PD98059 PDGF inhibit treatment-induced increase
U0126 PDGF inhibit treatment-induced increase

S773-p - Rb (mouse)
Modsite: STRPPtLsPIPHIPR SwissProt Entrez-Gene
Orthologous residues
Rb (human): S780‑p, Rb (mouse): S773‑p, Rb (rat): S772‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
PD98059 PDGF no effect upon treatment-induced increase

S788-p - Rb (mouse)
Modsite: sPyKFsssPLRIPGG SwissProt Entrez-Gene
Orthologous residues
Rb (human): S795‑p, Rb (mouse): S788‑p, Rb (rat): S787‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  3T3 (fibroblast), HEK293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase
PD98059 PDGF inhibit treatment-induced increase